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Background: Regional differences in the adoption of transcatheter aortic valve implantation (TAVI) technology have emerged since European CE 
mark approval in 2007. Factors that may influence TAVI adoption and therefore inequitable patient access have not been described.
methods: TAVI use was determined across 11 European nations: Germany, France, Italy, the United Kingdom (UK), Spain, The Netherlands, 
Switzerland, Belgium, Portugal, Denmark and Ireland. The following national economic indices and healthcare parameters were assessed in order to 
establish factors associated with TAVI use: (1) the volume-indexed gross domestic product (GDP) per capita adjusted for purchasing power; (2) the 
proportion of GDP spent on healthcare; (3) the total healthcare expenditure (US dollars) per capita; (4) the principal source of healthcare funding 
(social insurance or taxation); and (5) the system of TAVI reimbursement (local or national negotiation).
results: Between 2007-2011, a cumulative total of 34504 patients underwent TAVI in the 11 study nations. The volume-indexed GDP per capita 
was not associated with TAVI use (r=0.53, p=0.100). In contrast, strong and significant linear correlation was found between TAVI use and healthcare 
spending as a percentage of GDP (r=0.68, p=0.025) and net healthcare expenditure per capita (r=0.82, p=0.003). A trend towards increased TAVI 
use was found in those nations where social insurance was the principal source of healthcare funding compared to those with principally taxation 
funding (546.4±360.8 versus 269.4±194.2 implants per million ≥75 years, p=0.054). The system of reimbursement did not influence TAVI use, 
however a significantly lower number of implants per center occurred in nations where reimbursement was performed via local negotiation compared 
to national level diagnosis-related group based reimbursement (15.7±9.1 versus 43.2±28.0, p=0.004).
conclusions: TAVI use across Western Europe is influenced by a nation’s proportion of GDP spent on healthcare and the net healthcare 
expenditure per capita. Taxation as the principle source of healthcare funding and local negotiation of TAVI reimbursement appear to be associated 
with lower TAVI usage.
